Autologous AXL-targeted CAR T-cells CCT301-38

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.

**Synonyms:** - Autologous Anti-AXL CAR T Cells CCT30138 - Autologous CAR T-cells Targeting AXL CCT301-38 - CCT301 38 - CCT301-38 - CCT30138 CAR T Cells